Quick Overview: This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... Closing remarks from day two of the Advancing Generic
Agdd 2024 D1s14 Drug Device - Detailed Overview & Context
This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... Closing remarks from day two of the Advancing Generic This presentation recognized the significant challenges associated with conducting comparative clinical endpoint (CCEP) ... This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ... FDA experts demonstrate the FDA's Generic
This presentation described different long-acting injectable (LAI) products and recognized regulatory and scientific challenges for ... The first of three Q&A discussion panels from day two of the Advancing Generic This presentation described sources of ANDA Program statistics and provided insight on key performance metrics. The session ... This presentation examined In Vitro Release Testing (IVRT) for Closing remarks from day one of the Advancing Generic This presentation described how ongoing research contributes to the evolution of Product-Specific Guidances (PSGs) for topical ...
This presentation discussed in silico methodologies for topical products applied to the skin, with particular focus on dermal ... This presentation discussed the complexity of generic oligonucleotides and RLD-equivalence considerations, while reviewing key ... This presentation assessed Critical Quality Attributes (CQA) risks for oral solution and suspension products and described first ... The first of four Q&A discussion panels from day one of the Advancing Generic This presentation provided an overview of the M13 guideline series and the final M13A guideline, highlighting major changes ... The final Q&A discussion panel from day two of the Advancing Generic
This presentation explored the critical need for improved In Vitro Release Testing (IVRT) methods for complex The second of four Q&A discussion panels from day one of the Advancing Generic
